Sosei, Mundipharma agree to develop sublingual fentanyl spray for cancer pain

By Lisa Kerner

Charlotte, N.C., June 27 - Sosei Co. Ltd. said it has entered into an agreement with Mundipharma International Corp. Ltd. for the development and commercialization of Sosei's novel sublingual fentanyl spray for cancer breakthrough pain, AD 923, in Europe and other international markets, excluding North America and Japan.

Under the agreement, Sosei will develop and register AD 923, while Mundipharma will manufacture, market and sell AD 923 in licensed territories.

In addition, Sosei will receive up to £17.5 million in upfront and milestone payments as well as double digit royalties on product sales.

The worldwide market for cancer breakthrough pain drug treatment is about $1.5 billion, according to a company news release.

Sosei is a Tokyo-based biopharmaceutical company.

Bermuda-based Mundipharma is one of the Purdue/Mundipharma/Napp pharmaceutical companies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.